Mid-term survival of the Optimys short stem: A prospective case series of 500 patients

BACKGROUND In recent years,there has been an increase in the number of total hip arthroplasty procedures in the younger patient population.This active group has higher expectations of their prosthesis in comparison to the older population,and there is a greater physical demand for the prosthesis.Short femoral stems were in-troduced to retain proximal bone stock and joint biomechanics and became more common to implant in this specific population.Currently,the long-term survival and functional outcomes of various short stems are still being investigated in different clinics.AIM To determine the 5-year survival of the Optimys hip stem.METHODS This was a prospective multicenter cohort study of 500 patients conducted in two hospitals in the Netherlands.All patients received the Optimys short stem(Mathys Ltd,Bettlach,Switzerland).The primary outcome measure was survival of the hip stem,with revision as the endpoint.The secondary outcome measurements included patient-reported outcome measures(PROMs).Kaplan-Meier analysis was used to calculate the 5-year survival rate.Log-minus-log transformation was performed to calculate the 95%confidence interval(95%CI).Mixed model analyses were performed to assess the course of the PROMs during the 1st 2 years after surgery.Analyses were modeled separately for the 1st and 2nd years to calculate the yearly change in PROMs during both follow-up periods with accompanying 95%CIs.RESULTS The mean age of the total 500 patients was 62.3 years(standard deviation:10.6)and 202 were male(40%).At a median follow-up of 5.5 years(interquartile range:4.5-6.7),7 patients were deceased and 6 revisions were registered,for infection(n=3),subsidence(n=2)and malposition(n=1).This resulted in an overall 5-year survival of 98.8%(95%CI:97.3-99.5).If infection was left out as reason for revision,a stem survival of 99.4%(95%CI:98.1-99.8)was seen.Baseline questionnaires were completed by 471 patients(94%),317 patients(63%)completed the 1-year follow-up questionnaires and 233 patients(47%)completed the 2-year follow-up.Both outcome measures significantly improved across all domains in the 1st year after the operation(P<0.03 for all domains).In the 2nd year after surgery,no significant changes were observed in any domain in comparison to the 1-year follow-up.CONCLUSION The Optimys stem has a 5-year survival of 98.8%.Patient-reported outcome measures increased significantly in the 1st postoperative year with stabilization at the 2-year follow-up.

5-hydroxymethyl-2-furfural prolongs survival and inhibits oxidative stress in a mouse model of forebrain ischemia

In the present study, we hypothesized that 5-hydroxymethyl-2-furfural could attenuate ischemic brain damage by reducing oxidative injury. Thus, mice were subjected to bilateral common carotid artery occlusion to establish a model of permanent forebrain ischemia. The mice were intraperitoneally injected with 5-hydroxymethyl-2-furfura130 minutes before ischemia or 5 minutes after ischemia. The survival time of mice injected with 5-hydroxymethyl-2-furfural was longer compared with untreated mice. The mice subjected to ischemia for 30 minutes and reperfusion for 5 minutes were intraperitoneally injected with 5-hydroxymethyl-2-furfural 5 minutes prior to reperfusion, which increased superoxide dismutase content and reduced malondialdehyde content, similar to the effects of Edaravone, a hydroxyl radical scavenger used for the treatment of stroke. These findings indicate that intraperitoneal injection of 5-hydroxymethyl-2-furfural can prolong the survival of mice with permanent forebrain ischemia. This outcome may be mediated by its antioxidative effects.

No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages Ⅱ and Ⅲ gastric cancer

BACKGROUND The prognosis of gastric cancer in an advanced stage remains poor. The exact efficacy of the use of intraoperative sustained-release chemotherapy with 5-fluorouracil(5-FU) in advanced-stage gastric cancer is still unelucidated.AIM To explore the long-term survival benefit of using sustained-release 5-FU implants in stage Ⅱ and stage Ⅲ gastric cancer patients.METHODS Patients with gastric cancer in a locally advanced stage and who underwent an R0 radical resection between Jan 2014, to Dec 2016, in this single institution were included. Patients with pathological diagnoses other than adenocarcinoma were excluded. All included patients were grouped according to whether intraoperative sustained-release(SR) chemotherapy with 5-FU was used or not(NSR). The primary end-point was 5-year overall survival. Kaplan–Meier method with logrank test was used to analyze the overall survival of patients and Cox analysis was used to analyze prognosis factors of these patients.RESULTS In total, there were 563 patients with gastric cancer with locally advanced stage, who underwent an R0 radical resection. 309 patients were included in the final analysis. 219(70.9%) were men, with an average age of 58.25 years. Furthermore, 56(18.1%) received neoadjuvant chemotherapy, and 191(61.8%) were in TNM stage Ⅲ. In addition, 158 patients received intraoperative sustainedrelease chemotherapy with 5-FU and were included in the SR group, while the other 161 patients were included in the NSR group. The overall complication rate was 12.94% in the whole group and 10.81%, 16.46% in SR and NSR groups, respectively. There were no significant differences between the two groups in overall survival and complication rate(P > 0.05). The multivariate cox analysis indicated that only N Stage and neoadjuvant therapy were independent influencing factors of survival.CONCLUSION Intraoperative sustained-release chemotherapy usage with 5-FU, did not improve the survival of patients who underwent an R0 radical resection in locally advanced stage of gastric cancer.

PIK3CA and TP53 mutations predict overall survival of stage Ⅱ/Ⅲ colorectal cancer patients

AIM To investigate the predictive value of PIK3 CA and TP53 mutation status in colorectal cancer(CRC) patients treated with 5-fluorouracil-based chemotherapy.METHODS In this study, a total of 315 patients with histologically proven CRC were enrolled from Yangpu Hospital affiliated to Shanghai Tongji University between 2007 and 2011. Of these patients, 241 with stage Ⅱ/Ⅲ CRC received 5-fluorouracil-based adjuvant chemotherapy. Formalin-fixed paraffin-embedded lesion samples of the patients with curatively resected CRC were collected.Next-generation sequencing was performed to identify somatic gene mutations. The correlation of PIK3 CA and TP53 mutation status with overall survival(OS) was analyzed using a Cox proportional hazard model and the Kaplan-Meier method.RESULTS Among the 241 patients with stage Ⅱ/Ⅲ in this cohort, the PIK3 CA and/or TP53 mutation was detected in 177 patients, among which 54 patients had PIK3 CA and TP53 double mutations. The PIK3 CA or TP53 mutation was not significantly correlated with OS in univariate and multivariate analyses. Compared with patients without PIK3 CA and TP53 mutations, those with double PIK3 CA-TP53 mutations showed a significantly worse survival(univariate HR = 2.21; 95%CI: 1.15-4.24; multivariate HR = 2.02; 95%CI: 1.04-3.91). The PIK3 CA mutation located in the kinase domain showed a trend toward a shorter OS compared with wild-type tumors(multivariate HR = 1.56; 95%CI: 1.00-2.44; P = 0.052). The Kaplan-Meier curve showed that patients harboring the PIK3 CA mutation located in the kinase domain had a worse clinical outcome than those with wild-type status(Log-rank P = 0.041)CONCLUSION Double mutation of PIK3 CA and TP53 is correlated with a shorter OS in stage Ⅱ/Ⅲ CRC patients treated with 5-fluorouracil-based therapy.

miRNA-6507增强宫颈癌细胞顺铂敏感性及其机制探讨

目的:探讨miRNA-6507对宫颈癌细胞顺铂敏感性的影响及其机制。方法:通过TCGA数据库下载宫颈癌相关miRNA数据及临床数据,分析癌旁组织与癌组织间miRNA表达差异,并分析得到与患者生存期相关的miRNA;通过RT-qPCR验证所得miRNA在宫颈正常细胞与宫颈癌细胞间表达差异。选取与患者5年生存率相关的miRNA,将miRNA模拟物及对照转染至宫颈癌细胞系中,MTT检测细胞增殖,对转染后的细胞加入顺铂,检测细胞对顺铂的敏感性。结果:分析发现TCGA数据库宫颈癌标本中共有256个肿瘤组织,2个癌旁组织;通过edgeR分析发现宫颈癌相关的1881个miRNA中肿瘤组织同癌旁组织相比,表达上调的有19个,表达下降的有70个;对这89个miRNA分别分为高表达组和低表达组,进行生存分析结果发现,miRNA-140、miRNA-145、miRNA-200c、miRNA-6507与患者的生存期相关,miRNA-140、miRNA-145、miRNA-6507高表达患者生存期较长,miRNA-200c高表达患者生存期较短。RT-qPCR结果显示,在宫颈癌细胞系Caski、HCC94、Siha中miRNA-140的表达同宫颈细胞H8相比显著升高,在C33A和Hela细胞中miRNA-140无显著性差异。在所有的宫颈癌细胞中miRNA-145的表达均下降,该结果与生存分析一致;在宫颈癌细胞Caski和HCC94中miRNA-200c的表达上调,这与生存分析的结果相同,在C33A、Hela和Siha细胞中miRNA-200c的表达没有显著变化;在验证的5种宫颈癌细胞中miRNA-6507的表达量均低于正常细胞系H8,该结果同生存分析一致。MTT结果显示,C33A和Siha转染miRNA-6507模拟物后,其细胞活力均未受到影响,对转染后的细胞进行顺铂处理,结果显示转染miRNA-6507的细胞活力降低。结论:miRNA-6507可增强宫颈癌细胞的顺铂敏感性,有望成为宫颈癌治疗的候选miRNA靶点。

survivin反义核酸增强PANC-1细胞对5-Fu敏感性的研究

目的研究survivin反义核酸诱导胰腺癌细胞株PANC1的凋亡和增强对5Fu敏感性的影响。方法我们应用构建的survivin反义核酸真核表达载体电转染PANC1细胞,RTPCR检测survivinmRNA表达,细胞计数和MTT实验测定转染后细胞对5Fu敏感性,流式细胞仪检测细胞凋亡。结果survivin反义核酸可抑制PANC1细胞中survivinmRNA的表达,并能抑制PANC1细胞生长,提高PANC1对5Fu敏感性,流式细胞仪检测凋亡率明显增加。结论survivin反义核酸能增强5Fu诱导的PANC1细胞凋亡,联合survivin反义核酸和5Fu可以改善胰腺癌的治疗效果。

乳腺癌组织lncRNA CASC2、miR-532-3p表达水平与患者术后5年内生存的相关性

目的探究乳腺癌(BC)组织长链非编码RNA癌易感性候选基因2(lncRNA CASC2)、微小RNA-532-3p(miR-532-3p)表达与患者术后5年内生存的相关性。方法选择2015年1月—2018年6月大同市第五人民医院普通外科收治BC患者127例,术中收集BC组织及癌旁正常组织,荧光定量PCR法检测BC组织和癌旁正常组织中lncRNA CASC2、miR-532-3p表达;对BC患者术后进行为期5年的随访,记录患者5年内生存和死亡情况。比较癌旁正常组织和BC组织lncRNA CASC2及miR-532-3p表达,BC组织中lncRNA CASC2和miR-532-3p表达在不同临床病理特征中的差异,生存组和死亡组临床病理特征和BC组织中lncRNA CASC2及miR-532-3p表达的差异。分析BC组织lncRNA CASC2、miR-532-3p表达的相关性;BC组织中lncRNA CASC2和miR-532-3p表达与术后5年内生存的关系;影响BC患者术后5年内生存的因素;lncRNA CASC2、miR-532-3p对BC患者术后5年内生存的预测价值。结果BC组织中lncRNA CASC2表达水平低于癌旁正常组织,miR-532-3p表达水平高于癌旁正常组织(t/P=38.239/<0.001,49.406/<0.001);肿瘤直径≥2 cm、TNM分期Ⅲ期、肿瘤低分化、淋巴结转移者比例lncRNA CASC2低表达组高于高表达组,而miR-532-3p低表达组低于高表达组(lncRNA CASC2:χ^(2)/P=17.361/<0.001、17.052/<0.001、14.694/<0.001、13.173/<0.001;miR-532-3p:χ^(2)/P=10.733/0.001、9.813/0.002、10.134/0.001、7.444/0.006);127例BC患者术后随访5年,生存99例(生存组),死亡28例(死亡组),肿瘤直径≥2 cm、TNM分期Ⅲ期、肿瘤低分化、淋巴结转移者比例及miR-532-3p表达水平死亡组高于生存组,而lncRNA CASC2表达水平死亡组低于生存组[χ^(2)(t)/P=5.211/0.022、27.149/<0.001、27.990/<0.001、4.590/0.032、19.155/<0.001、10.818/<0.001];BC组织中lncRNA CASC2与miR-532-3p表达呈负相关(r/P=-0.561/<0.001);lncRNA CASC2高表达组BC患者术后5年内总生存率为89.23%(58/65),高于lncRNA CASC2低表达组66.13%(41/62)(χ^(2)/P=9.854/0.002);miR-532-3p高表达组BC患者术后5年内总生存率为65.57%(40/61),低于miR-532-3p低表达组89.39%(59/66)(χ^(2)/P=10.466/0.001);肿瘤直径≥2 cm、TNM分期Ⅲ期、肿瘤低分化、有淋巴结转移、lncRNA CASC2低表达、miR-532-3p高表达均是影响BC患者术后5年内生存的独立危险因素[HR(95%CI)=2.255(1.192~4.263)、2.143(1.252~3.666)、3.089(1.386~6.887)、2.219(1.223~4.026)、2.606(1.174~5.788)、2.855(1.592~5.120)];lncRNA CASC2、miR-532-3p及二者联合预测BC患者术后5年内生存的AUC分别为0.840、0.852、0.908,二者联合预测的AUC大于lncRNA CASC2、miR-532-3p各自单独预测的AUC(Z/P=2.246/0.025、2.033/0.042)。结论BC组织中lncRNA CASC2表达下调,miR-532-3p表达上调,且术后5年内死亡的BC患者较存活患者变化更显著,二者表达与临床病理特征相关,对预测BC患者术后5年内生存情况价值较高。

食管癌内镜活检组织中Survivin和Mcm5的表达及临床意义

目的研究凋亡抑制因子survivin和增殖因子Mcm5在食管鳞癌发生发展过程中表达的意义及其相互关系。方法采用免疫组织化学(S-P)法检测了85例食管胃镜活检存档蜡块标本中survivin和Mcm5的表达情况,其中11例食管正常黏膜,9例不典型增生,10例原位癌及55例浸润癌。结果食管活检组织中,survivin和Mcm5蛋白在由正常向癌转变的过程中,表达逐渐增高,两者在正常黏膜中的表达均明显低于不典型增生、原位癌及浸润癌(P<0.05);survivin蛋白表达与Mcm5蛋白表达之间呈正相关关系(P<0.01)。结论食管癌的发生发展过程涉及凋亡抑制因子survivin的激活及增殖因子Mcm5功能的增强,同时检测胃镜活检标本中两个指标有助于提高食管癌早期诊断的阳性率。

Thirty-one patients with primary hepatocellular carcinoma survived for more than 5 years after hepatectomy

Objective: To investigate the factors affecting progno- sis of patients with primary hepatocellular carcinoma (PHC) after resection. Methods: From 1976 to 1992, 213 patients with PHC treated with hepatectomy were followed up for more than 5 years. Thirty-one of the patients who had sur- vived for more than 5 years were compared with 56 patients who had survived for less than 5 years. Results: Early detection of tumor, radical resection, number of tumors, capsule formation, operation safe distance, presence of portal tumor embolus, pre- sence of cirrhosis and tumor size were important fac- tors affecting the prognosis of patients with PHC. The proportion of small liver cancer in the patients who had survived for more than 5 years was greatly larger than that in the control group. Conclusions: Early detection of tumor and radical re- section are of value in raising the 5-year survival rate. Much remains to be investigated about the rela- tionship between safe margin distance and prognosis of patients with PHC.

Nanomolar concentration of alpha-synuclein enhances dopaminergic neuronal survival via Akt pathway

Although alpha-synuclein is generally thought to have a pathological role in Parkinson＇s disease, accumulative evidence exists that alpha-synuclein has a neuroprotective effect. The aim of this study was to evaluate the effect of extracellular alpha-synuclein on dopaminergic cell survival. We assessed cell viability using the 3-（4,5-dimethyt-thiazol-2-yt）-2,5-diphenyltertazolium bromide （MTT） assay both in undifferentiated SH-SY5Y （SHSY） cells and neuronally-differentiated SH-SY5Y （ndSHSY） cells after 24 hour treatment with monomeric alpha-synuclein at various concentrations （0 [control], 50, 100 nmol/L, 1 IJmol/L）. To determine whether cell viability assessed by MTT assay was affected by cell proliferation, 5-bromo-2＇-deoxyuridine （BrdU） incorporation assay was per- formed. Level of both Akt and phosphorylated Akt was measured using western blot method in ndSHSY cells with or without 24 hour alpha-synuclein treatment. Cell viability was increased in ndSHSY cells at the nanomolar concentration of alpha-synuclein, but not in SHSY cells. Proportion of BrdU-positive ndSHSY cells was decreased in alpha-synuclein-treated group compared with control group. Level of phosphorylated Akt in alpha-synuclein-treated group was higher compared with the control group. Our study shows that extracellular alpha-synuclein at nanomolar concentra- tion benefits dopaminergic cell survival via Akt pathway.

Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX

AIM: To explore if vascular endothelial growth factor receptor-3 (VEGFR-3) and carcinoembryonic antigen (CEA) can predict overall survival in advanced gastric cancer.METHODS: VEGFR-3 level was assessed by enzymelinked immunosorbent assay,and CEA was assessed by chemiluminescence immunoassay in the sera of 81 advanced gastric cancer patients before treatment with oxaliplatin plus 5-fluorouracil and folinic acid.RESULTS: Median survival time in patients with a low serum VEGFR-3 level was significantly longer than in those with a higher VEGFR-3 level (15.4 mo vs 7.7 mo,P < 0.001).Patients with a low CEA level had a longer survival than those with a higher CEA level (15.8 mo vs 8.6 mo,P < 0.001).Thirty-nine patients with low VEGFR-3 and low CEA levels had a median survival of 19.7 mo (P = 0.0006).The hazard ratio for patients with a high VEGFR-3 level was 2.443 (P = 0.002).CONCLUSION: High serum VEGFR-3 level is correlated significantly with poor survival.In patients with a high serum level of VEGFR-3,alternative chemotherapy regimens should be considered.

Laser-assisted dacryocystorhinostomy in nasolacrimal duct obstruction：5-year follow-up

AIM：To evaluate the long-term sucess rate of laserassisted dacryocystorhinostomy （L-DCR） in patients with nasolacrimal duct obstruction （NDO）.METHODS：Forty-one eyes of forty patients aged between 21-85y （mean 56.7y） who underwent L-DCR for the treatment of NDO were included in this retrospective,non-randomized study. The follow-up time was 72mo.Functional sucess was defined as the disappearance of epiphora under normal conditions and the presence of a patent ostium on lacrimal irrigation. Anatomical success was defined as a patent lacrimal passage on syringing besides continuing epiphora. Surgical failure was defined as persistent epiphora and closed ostium.RESULTS：Twenty-seven of 40 patients （67.5%） were female and 13 of 40 patients （32.5%） were male. The NDO was right-sided in 17 （42.5%） patients and left-sided in 22（55%） patients whereas 1 （2.5%） patient had undergone bilateral surgery. In 11 （27.5%） patients there were additional nasal abnormalities requiring simultaneous surgical approach. The average time for L-DCR was 26.50±4.9min（16-39min） and the average total amount of laser energy used was 287±27.9 J （239-367 J）. At the 5y follow-up, anatomical sucess rate was 75.0%（30 patients） and functional success rate was 65.0%（26 patients）, whereas surgical failure was seen in 25%（10 patients）. Revision of surgery was performed in 10 cases （25.0%）; failure of revision surgery was seen in 2 cases（5.0%）.CONCLUSION： Transcanalicular L-DCR is a reliable and fast procedure in the treatment of NDO. It can be alternative to external DCR which is accepted as the gold standard currently. The functional and anatomical success rate is higher in the first months and years, but still satisfactory at fifth year.

Survival of patients with gastric cancer surgically treated at the National Cancer Center of China from 2011 to 2018 according to stage at diagnosis

Objective:The postoperative survival rates of patients with gastric cancer at different stages treated at the National Cancer Center(NCC)of China have not been reported.Therefore,we evaluated the survival of patients with gastric cancer who underwent surgery at the NCC from 2011 to 2018 to provide baseline information for further studies.Methods:We identified 7,301 patients with primary gastric carcinoma who underwent surgery at the NCC be-tween January 2011 and May 2018;among these,5,008 patients were enrolled in this study.Follow up was completed on April 30,2020.We analyzed the 5-year survival according to the stage,sex,age,and other clini-copathological features.Results:Five-year survival rates of patients with pTNM stages ⅠA,ⅠB,ⅡA,ⅡB,ⅢA,ⅢB,ⅢC,and Ⅳ treated at the NCC were 94.9%,91.8%,86.5%,76.1%,61.1%,44.2%,29.7%,and 8.1%,respectively,which were similar to those reported in Japan during the same period.Five-year survival rates of patients with ypTNM stages I,II,III,and IV were 93.1%,63.2%,27.2%,and 0.0%,respectively.In multivariable analysis,age,signet ring cell carcinoma,adjuvant chemotherapy,and degree of differentiation were revealed as important prognostic factors.Conclusion:The survival rates of patients with gastric cancer treated at the NCC have been significantly improved,reaching the levels of Japan in the same period.

胃癌患者血清p53、PDCD-5、survivin表达水平及其联合应用的价值

目的探讨胃癌患者血清p53、程序性细胞死亡分子-5(PDCD-5)、细胞凋亡抑制蛋白存活素(survivin)表达水平及其联合应用的价值。方法选择2012年9月到2015年9月在本院被确诊的108例胃癌患者,收集同期同年龄阶段健康体检者的54例血清样本作为对照组。分析胃癌患者的一般资料,包括年龄、性别、TNM分期、肿瘤大小、肿瘤分化程度、肿瘤浸润深度以及有无淋巴结转移;采用ELISA检测血清样品中p53、PDCD-5和survivin表达水平;治疗后随访患者的生存时间;采用单因素生存分析Kaplan-Meier绘制生存曲线。结果与对照组相比,胃癌患者血清中PDCD-5的表达水平显著下降(P<0.05),p53和survivin的表达水平显著升高(P<0.05);胃癌组患者血清p53、PDCD-5和survivin的表达水平与肿瘤直径、分化程度、浸润深度、TNM分期以及是否合并淋巴结转移有关(P<0.05);生存分析显示,胃癌患者血清中p53、survivin高表达患者3年总生存率和无病生存率显著低于p53、survivin低表达患者(P<0.05);PDCD-5、survivin高表达患者3年总生存率和无病生存率显著高于PDCD-5、survivin低表达患者(P<0.05)。结论胃癌患者血清p53、survivin低表达且PDCD-5高表达可以提高其3年总生存率和无病生存率,临床有望作为其预后标识物。

血清转录因子样蛋白5预测子宫内膜癌及其预后的临床价值

目的探讨血清转录因子样蛋白5(TCFL5)预测子宫内膜癌及其预后的临床价值。方法选取2016年1月至2018年6月邯郸市妇幼保健院收治的120例子宫内膜癌患者作为试验组,选取同期同院行健康体检的120名女性作为对照组。比较TCFL5在血清、子宫内膜癌组织、不同临床分期的表达水平,采用受试者工作特征(ROC)曲线的曲线下面积(AUC)分析血清TCFL5表达水平对子宫内膜癌的预测价值,采用单因素及多因素Cox回归分析血清TCFL5表达水平对子宫内膜癌的预后影响。结果试验组血清TCFL5表达水平高于对照组(P<0.001);与癌旁组织比较,TCFL5在癌组织中高表达(P<0.001);临床分期越晚,TCFL5表达水平越高(P<0.05)。TCFL5表达水平对子宫内膜癌的预测性能较高(AUC=0.907,95%CI:0.878~0.937)。单因素及多因素Cox回归分析显示,年龄和TCFL5表达水平是子宫内膜癌预后的独立影响因素(P<0.05)。结论TCFL5在子宫内膜癌患者血清中表达水平显著升高,其可作为诊断子宫内膜癌的标志物,且对患者预后具有较好的预测价值。

Five-Year Survivors of Non-Small Cell Lung Cancer Patients with Positive Pleural Lavage Cytology

Background: The pleural lavage cytology (PLC) for non-small cell lung cancer (NSCLC) patients has been reported as a significant prognostic factor. The aim of this study is to clarify the clinicopathological characteristics of 5-year survivors of patients with positive PLC. Methods: Among 401 resected NSCLC patients, 30 (7.48%) patients with positive PLC were reviewed retrospectively. Results: Only 7 of 30 patients (23.3%) survived more than 5-year. There were no differences in age, gender, histology, pT status and pN status between 5-year survivors and non-survivors. On the other hand, the serum carcinoembryonic antigen (CEA) level was significantly higher in non-survivors. Among these 5-year survivors, 4 of 7 patients died of NSCLC recurrences more than 5 years after surgery. Remaining 3 patients survived without cancer recurrences. Interestingly these 3 survivors had not received any adjuvant therapies after surgery. Conclusion: None of the 5-year survivor with positive PLC had high serum CEA level. Furthermore 5-year survival did not equal to cure in NSCLC patients with positive PLC.

New 5-Year Plan to See Revolutionary Changes

In the next five years,China will place more emphasis on science and technolgy, education,and health care in policy and investment.

DLGAP5在肝细胞癌中的表达及临床意义

目的:探讨Discs大同源物相关蛋白5(Discs large homolog associated protein 5,DLGAP5)在肝细胞癌(hepatocellular carcinoma,HCC)中的表达及其临床意义。方法:采用免疫组化法检测144对肝细胞癌组织和对应的癌旁组织样本中DLGAP5蛋白的表达,分析其表达与患者临床病理特征的关系,绘制Kaplan-Meier生存曲线分析DLGAP5表达对患者预后的影响。结果:肝细胞癌组织中DLGAP5表达阳性率77.8%,高于癌旁组织的阳性率38.9%,差异有统计学意义(P<0.01)。DLGAP5表达与肿瘤直径、TNM分级、脉管癌栓及肿瘤包膜完整性有关(均P<0.05),而与患者性别、年龄、乙型肝炎表面抗原、肝硬化及远处转移无关(均P>0.05)。Kaplan-Meier生存曲线分析显示,DLGAP5高表达组患者总生存率显著低于DLGAP5低表达组患者,差异具有统计学意义(P<0.05)。结论:DLGAP5蛋白在肝细胞癌中表达增高,其高表达与患者的预后不良有关。

X-射线修复交叉互补蛋白5在脑胶质瘤中的表达及临床意义

目的分析X-射线修复交叉互补蛋白5(XRCC5)在脑胶质瘤(brain glioma,BG)中的表达水平及其与临床病理特征和预后的关系。方法利用癌症基因图谱(TCGA)数据库的RNA测序数据分析XRCC5在636例BG[468例低分级脑胶质瘤(LGG),168例多形性胶质母细胞瘤(GBM)]与正常脑组织的表达差异,比较XRCC5表达水平与年龄、性别、病理分级、生存期以及肿瘤增殖相关抗原67(MKI67)表达水平的相关性。对BG组织芯片(47例LGG、75例GBM及3例正常脑组织)进行XRCC5免疫组化染色,进一步验证XRCC5表达水平与BG病理分级的关系。结果TCGA分析结果显示,XRCC5在BG组织中的表达水平高于正常脑组织(P<0.001),在GBM组的表达水平高于LGG组(P<0.001);XRCC5表达水平与BG病理分级呈正相关(P<0.001),与MKI67表达水平呈正相关(P<0.001);XRCC5高表达组生存期长于低表达组(P<0.001);不同性别、不同年龄段XRCC5表达水平差异均无统计学意义(P均>0.05);XRCC5的免疫组化染色结果显示,肿瘤组织中XRCC5表达水平高于正常人脑组织(P<0.05)。结论XRCC5在BG组织中升高,且与恶性肿瘤的生物标记物MKI67呈正相关。XRCC5表达越高,患者的预后越好,生存期越长。